RT Journal Article
SR Electronic
T1 Impact of maternal antibodies and microbiota development on the immunogenicity of oral rotavirus vaccine in African, Indian, and European infants: a prospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.02.20224576
DO 10.1101/2020.11.02.20224576
A1 Parker, Edward P. K.
A1 Bronowski, Christina
A1 Sindhu, Kulandaipalayam Natarajan C.
A1 Babji, Sudhir
A1 Benny, Blossom
A1 Carmona-Vicente, Noelia
A1 Chasweka, Nedson
A1 Chinyama, End
A1 Cunliffe, Nigel A.
A1 Dube, Queen
A1 Giri, Sidhartha
A1 Grassly, Nicholas C.
A1 Gunasekaran, Annai
A1 Howarth, Deborah
A1 Immanuel, Sushil
A1 Jere, Khuzwayo C.
A1 Kampmann, Beate
A1 Lowe, Jenna
A1 Mandolo, Jonathan
A1 Praharaj, Ira
A1 Rani, Bakthavatsalam Sandya
A1 Silas, Sophia
A1 Srinivasan, Vivek Kumar
A1 Turner, Mark
A1 Venugopal, Srinivasan
A1 Verghese, Valsan Philip
A1 Darby, Alistair C.
A1 Kang, Gagandeep
A1 Iturriza-Gómara, Miren
YR 2020
UL http://medrxiv.org/content/early/2020/12/11/2020.11.02.20224576.abstract
AB Identifying risk factors for impaired oral rotavirus vaccine (ORV) efficacy in low-income countries may lead to improvements in vaccine design and delivery. We measured maternal rotavirus antibodies, environmental enteric dysfunction (EED), and bacterial gut microbiota development among infants receiving two doses of Rotarix in India (n = 307), Malawi (n = 119), and the UK (n = 60), using standardised methods across cohorts. ORV shedding and seroconversion rates were significantly lower in Malawi and India than the UK. Maternal rotavirus-specific antibodies in serum and breastmilk were negatively correlated with ORV response in India and Malawi, and this was mediated partly by a reduction in ORV replication. In the UK, ORV replication was not inhibited despite comparable maternal antibody levels. In both India and Malawi, pre-vaccination microbiota diversity was negatively correlated with ORV immunogenicity, suggesting that high early-life microbial exposure may contribute to impaired vaccine efficacy.Competing Interest StatementM.I.G. has received research grants from GSK and Merck, and has provided expert advice to GSK. K.C.J. and N.A.C. have received investigator-initiated research grant support from GSK. N.A.C. has received research grant support and honoraria for participation in rotavirus vaccine data safety monitoring committee meetings from GSK.Clinical TrialCTRI/2015/11/006354Clinical Protocols https://bmjopen.bmj.com/content/7/3/e016577.long Funding StatementThe UK and Malawi sites were funded by the UK Medical Research Council and the UK Department for International Development (Newton Fund MR/N006259/1). M.I.G. is partly supported by the NIHR HPRU in Gastrointestinal Infections. K.C.J. is funded by a Wellcome International Training Fellowship (number 201945/Z/16/Z). The site in India was funded by the Government of India's Department of Biotechnology.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board at the Christian Medical College (CMC) in Vellore, the College of Medicine Research and Ethics Committee in Blantyre, and the North West - Liverpool East Research Ethics Committee in Liverpool.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw sequence data generated during this study have been deposited in the European Nucleotide Archive (accession number PRJEB38948). Processed data and analysis code generated during this study are available on github (https://github.com/eparker12/RoVI). https://github.com/eparker12/RoVI